Organs-on-chip technology reveals new drug candidates for Lou Gehrig's disease

The investigation of amyotrophic lateral sclerosis (ALS) - also known as Lou Gehrig's disease - through muscle-on-a-chip technology has revealed a new drug combination that may serve as an effective treatment of the progressive neurodegenerative disease. These findings highlight organ-on-a-chip technologies - in which live conditions of the body are mimicked in a microfluidic cell culture - as promising platforms for testing drug candidates and investigating the pathogenesis of ALS, which remains largely unknown.

The disease currently impacts around 12,000 to 15,000 people in the U.S. ALS involves the loss of motor neurons in the spinal cord and motor cortex, which leads to progressive paralysis, muscle atrophy and death. While roughly 10% of ALS patients have a familial version of the disease, which can typically be traced back to a genetic mutation, 90% of patients have "sporadic ALS," which has no known familial links or causes. As the few FDA-approved drugs currently on the market for ALS lack full effectiveness, there is an urgent need for ALS therapy investigations in the clinic, using better clinical models that can go beyond the limitations of animal models. Here, Tatsuya Osaki and colleagues created disease-on-a-chip technology-based approach. It features a microfluidic chip loaded with healthy skeletal muscle bundles and induced pluripotent stem cell-derived, light-sensitive motor neurons from a sporadic ALS patient. Light was used to activate muscle contraction and control neural activity on the chips.

Compared to chips with non-ALS-patient-derived cells, the ALS-on-a-chip exhibited fewer and weaker muscle contractions, degraded motor neurons, and increased muscle cell death. Application of two neuroprotective molecules - rapamycin and bosutinib (both in clinical trials) - helped recover muscle contraction induced by motor neuron activity and improve neuronal survival in the chip-based model of disease. Importantly, each treatment on its own has a limited ability to penetrate the blood-brain barrier, but when combined, the molecular duo could efficiently cross blood-brain-barrier-like cell layers built onto the chip.

Tatsuya Osaki, Sebastien GM Uzel, Roger D Kamm1.
Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons.
Science Advances 10 Oct 2018, Vol. 4, no. 10. doi: 10.1126/sciadv.aat5847.

Most Popular Now

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

Amgen and UCB receive positive vote from FDA Advis…

Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advis...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

Merck welcomes ten new startups to its Innovation …

Merck, a leading science and technology company, today announced the ten startups that will be joining the seventh intake of its Accelerator program at the Merck Innovati...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Researchers call for big data infrastructure to su…

Researchers from the George Washington University (GW), the U.S. Food and Drug Administration (FDA), and industry leaders published in PLOS Biology, describing a standard...

New computational method reduces risk of drug form…

One major factor that determines the efficacy of a drug is the structure that its molecules form in a solid state. Changed molecular structures can entail that pills stop...